Evidence map›Paper›PMID 21940661›Full record

ArticleAmerican journal of physiology. Cell physiology2012

Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101.

Maximilian Stahl, Klaus Stahl, Marie B Brubacher, John N Forrest

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of physiology. Cell physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Key role of down-regulated in adenoma (bioRxiv : the preprint server for biology · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Structural mechanisms of CFTR function and dysfunction.The Journal of general physiology · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Molecular modelling and molecular dynamics of CFTR.Cellular and molecular life sciences : CMLS · 2017
    Review
  17. Article
  18. THE SHARK RECTAL GLAND MODEL: A CHAMPION OF RECEPTOR MEDIATED CHLORIDE SECRETION THROUGH CFTR.Transactions of the American Clinical and Climatological Association · 2016
    Article
  19. Value of Organoids from Comparative Epithelia Models.The Yale journal of biology and medicine · 2015
    Review
  20. Murine and human CFTR exhibit different sensitivities to CFTR potentiators.American journal of physiology. Lung cellular and molecular physiology · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maximilian StahlNephrology Division, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510-3222, USA.
Klaus Stahl
Marie B Brubacher
John N Forrest
Yale University · USMount Desert Island Biological Laboratory · US

Funding

WNT SIGNALING IN THE DEVELOPING GASTROINTESTINAL TRACTP20RR016463 · NCRR · MOUNT DESERT ISLAND BIOLOGICAL LAB · PI WRAY, CHRISTOPHER C · 2001 to 2011
$41.0M
THE EPITHELIA OF THE EYE--EFFECT OF ENVIRONMENTAL AGENTSP30ES003828 · NIEHS · MOUNT DESERT ISLAND BIOLOGICAL LAB · PI HENSON, JOHN H · 1987 to 2008
$4.1M
ADENOSINE RECEPTORS AND ION TRANSPORT IN EPITHELIAR01DK034208 · NIDDK · YALE UNIVERSITY · PI FORREST, JOHN N · 1986 to 2003
$1.6M
NCRR NIH HHS P20RR016463NIDDK NIH HHS DK 34208NIEHS NIH HHS P30-ES 3828
6 · The paper itself

Abstract

Comparison of diverse orthologs is a powerful tool to study the structure and function of channel proteins. We investigated the response of human, killifish, pig, and shark cystic fibrosis transmembrane conductance regulator (CFTR) to specific inhibitors of the channel: CFTR(inh)-172, glibenclamide, and GlyH-101. In three systems, including organ perfusion of the shark rectal gland, primary cultures of shark rectal gland tubules, and expression studies of each ortholog in cRNA microinjected Xenopus laevis oocytes, we observed fundamental differences in the sensitivity to inhibition by these channel blockers. In organ perfusion studies, shark CFTR was insensitive to inhibition by CFTR(inh)-172. This insensitivity was also seen in short-circuit current experiments with cultured rectal gland tubular epithelial cells (maximum inhibition 4 ± 1.3%). In oocyte expression studies, shark CFTR was again insensitive to CFTR(inh)-172 (maximum inhibition 10.3 ± 2.5% at 25 μM), pig CFTR was insensitive to glibenclamide (maximum inhibition 18.4 ± 4.4% at 250 μM), and all orthologs were sensitive to GlyH-101. The amino acid residues considered responsible by previous site-directed mutagenesis for binding of the three inhibitors are conserved in the four CFTR isoforms studied. These experiments demonstrate a profound difference in the sensitivity of different orthologs of CFTR proteins to inhibition by CFTR blockers that cannot be explained by mutagenesis of single amino acids. We believe that the potency of the inhibitors CFTR(inh)-172, glibenclamide, and GlyH-101 on the CFTR chloride channel protein is likely dictated by the local environment and the three-dimensional structure of additional residues that form the vestibules, the chloride pore, and regulatory regions of the channel.

Indexed as

Amino Acid SequenceAnimalsBenzoatesCystic Fibrosis Transmembrane Conductance RegulatorFemaleFundulidaeGlyburideGlycineHumansHydrazinesMaleMolecular Sequence DataSqualus acanthiasSwineThiazolidinesXenopus laevis3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinoneBenzoatesCystic Fibrosis Transmembrane Conductance RegulatorGlyburideGlycineHydrazinesN-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazideThiazolidines

Identifiers

PMID21940661
PMCPMC3328903
OpenAlexW2160821931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.